FTC sues to bar Amgen from major IP $28bn acquisition

18-05-2023

Muireann Bolger

FTC sues to bar Amgen from major IP $28bn acquisition

Marlon Trottmann / Shutterstock.com

The $27.8 billion acquisition would allegedly enable the pharma giant to stifle competition for thyroid eye disease and chronic refractory gout treatments | There is currently no market competition for the treatments.


Amgen, Horizon, FTC, US, pharma, US Federal Trade Commission, antitrust

More on this story

Amgen seals $28m deal for biotech
13-12-2022

LSIPR